Terns Pharmaceuticals Inc (NASDAQ:TERN) shares traded 23.14% higher at $11.23 on Wall Street last session.
TERN stock price is now 44.22% away from the 50-day moving average and 70.20% away from the 200-day moving average. The market capitalization of the company currently stands at $790.26M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $16, Mizuho recently initiated with Buy rating for Terns Pharmaceuticals Inc (NASDAQ: TERN). On June 07, 2023, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘ROTH MKM’ rates the stock as ‘Buy’
In other news, SEOKHO BRYAN YOON, Officer bought 10,000 shares of the company’s stock on Sep 10 ’24. The stock was bought for $91,200 at an average price of $9.12. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 10 ’24, Officer MARK J VIGNOLA bought 10,000 shares of the business’s stock. A total of $91,200 was incurred on buying the stock at an average price of $9.12. A total of 31.85% of the company’s stock is owned by insiders.
During the past 12 months, Terns Pharmaceuticals Inc has had a low of $3.26 and a high of $10.06. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 21.02, and a quick ratio of 21.02. The fifty day moving average price for TERN is $7.8753 and a two-hundred day moving average price translates $6.63555 for the stock.
The latest earnings results from Terns Pharmaceuticals Inc (NASDAQ: TERN) was released for 2024-06-30. The company reported revenue of $25.54 million for the quarter, compared to $21.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 20.69 percent.
Terns Pharmaceuticals Inc(TERN) Company Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
